University to StartupMarch 19, 2024 | 7:00 pm - 8:30 pm ET | CIC, Cambridge, MA
Attendees will have the option to join us in-person or online via Zoom.
Academic research is a critical source of new knowledge, a basic research engine that translates investigator curiosity, energy and resourcefulness into tools, insights and inventions that have the potential to change the world. Sadly, only 5-10 percent of patented academic inventions go on to become commercial products, and only a very small percentage of academic research even gets to the stage of filing a patent. What does it take to effectively translate academic research to commercial success?
Often, the path to commercialization begins with a start-up. The challenges in launching a start-up based on research emerging from academia are manifold. To say “it takes a village” would be a gross understatement. Tonight’s panelists, each having a key role in the academic research to commercialization continuum, will enlighten us with their experienced insights.
A question-and-answer session will follow the panel discussion, and the panelists will be available afterward for responses to individual questions.
(All times are USA Eastern time, webinars will not be recorded, except that ENET members can review a recording of this webinar after the meeting.)
This is a hybrid event. You may choose to participate in-person or online.
In-person Participation (check-in begins at 6:00 PM):
LOCATION: CIC, Cambridge MA
REFRESHMENTS: Pizza and soft drinks will be served.
Zoom links will be sent to all registrants after registration.
Cost and Reservations: This event is free for ENET members and $15 for non-members. Click here to learn how to become a member. To expedite sign-in for the event, we ask that everyone — members as well as non-members — pre-register. If you cannot pre-register, you are welcome to register in person at the door while seats are available.
Event ScheduleMarch 19, 2024
Shelley Amster, Cofounder, Chief Strategy and Growth Officer, 3Daughters, a unique company focused on Evolutionary Healthcare for Women. The first product is a frameless, magnetic, non hormonal intrauterine device (IUD) based on physics and geometry for long-acting contraception, designed to improve upon the outdated T-shape frame of current IUDs that causes pain, among other serious complications, Shelley has worked in the life science and health industries for more than 45 years beginning clinical & research in the field of fertility, andrology, IVF, male & female reproductive health. She is also the founder and principal at ShelleyCO, a life science business development consulting firm. Shelley is an advisor or board member for several emerging life science companies providing expertise in business development. Shelley is also a recognized conference producer for high quality life science programs and a prolific business connector, utilizing her well-curated network of industry leaders, KOLs, members of the investment community, entrepreneurs & innovators. Shelley remains an active mentor and role model for the entrepreneurs and scientists of tomorrow.
Richard Meiklejohn is the Innovation Leader at UMass Lowell, M2D2 where he plays a pivotal role in helping early-stage life sciences ventures form and accelerate their commercialization pathway. Leading a global accelerator program, he has worked with hundreds of different startups to support fundraising, strategy, and technical development. Previously, Richard led his own asset management company and collaborated on a number of pan-European research projects dedicated to improving economic activity and sustainability. He is a passionate advocate of entrepreneurship and can be found regularly promoting startups as a co-host on the Medtech Impact Podcast. When away from work, Richard enjoys visiting family and friends in Scotland, skiing, and is an avid sports fan.
Mark Namchuk is the Puja and Samir Kaul Professor of the Practice of Biomedical Innovation and Translation at Harvard Medical School. He Joined HMS is 2020 as the inaugural Executive Director of the school’s Therapeutics initiative and was appointed as the first Professor of the Practice at HMS in the Department of Biological Chemistry and Molecular Pharmacology in 2021. The therapeutics initiative looks to accelerate the progression of discoveries at HMS from breakthrough biological insight towards a medicine and includes a scientific core to support drug discovery efforts and an on-campus biotech incubator. The initiative also aims to train the inventors of tomorrow’s medicines and includes the therapeutics graduate program for PhD students and a masters in therapeutic sciences that will be launched in 2025.
Namchuk joined HMS after a 24-year research and development career in biotech. In 2015, he joined Alkermes as SVP of research and nonclinical and pharmaceutical development. Previously, he held a number of research positions over a 17 year career at Vertex including SVP of Research. During his time in biotech he played a key scientific or leadership role in drug discovery and development efforts across numerous areas including oncology, infectious disease, immunology, CNS disorders and orphan diseases. To date these programs have led to six approved drugs and an additional molecule in active Phase 3 clinical development.
Namchuk obtained a B.Sc. with honours in chemistry from the University of Alberta, a PhD in bio-organic chemistry from the University of British Columbia and was an HFSP post-doctoral fellow at UCSF.
Moderator & Organizers
Christos Hatzis is VP, Global Head of Translational Medicine at HiFiBio Therapeutics
Brian Hult is a founding partner of private equity firm Blue Nexus Ventures. He joined BNV from Cabot Boston Credit Union and Cabot Corporation. For over 9 years at Cabot Boston Credit Union he held the roles of Member and Chairman, Board of Directors and was responsible for the management of the funds of 800 members totaling over $7.4 AUM. Over the 9 years he held leadership roles conducting audits, loan reviews, credit underwriting, reviewing and revising policy compliance processes, and implementation of member growth strategies. For over 11 years at Cabot Corporation Mr. Hult held roles of increasing responsibility in New Product Chemistry, Process Engineering, and Strategic Market Development which resulted in the development of intellectual property, the scaling of new products from lab-scale to metric ton production scales, and commercial launches in Inkjet Printing, Automotive and Industrial Rubber, and Battery industries.He has a history of startups and experience in a variety of industries including internet gaming, performance and racing automotive aftermarket, aquaculture, clean tech, environmental, consulting and marketing & advertising. He holds a Masters of Science degree in Technology Entrepreneurship and a Masters of Science degree in Chemistry and Materials Science from Northeastern University and a Bachelors of Science in Chemistry with minors in Physics and Business Administration from Eastern Nazarene College.
Double check your email address – if it is incorrect, you will not get the email confirmation and the Zoom link.
REFUND POLICY: If you cancel your registration before the event, ENET will refund your registration fee in the form of a credit towards a future ENET event.